AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s

AgeneBio Receives Grant for Drug-Discovery Program Targeting Cognitive Decline in Alzheimer’s
AgeneBio has received a $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of a novel GABAdiscovery program targeting hippocampal overactivity in the brain, which is thought to contribute to neurodegeneration and cognitive decline in Alzheimer’s disease (AD) patients. AgeneBio’s pipeline of therapies is based on research showing that overactivity in the hippocampus (the part of the brain responsible for emotion, memory, and learning) contributes to cognitive impairment and drives neurodegeneration later on. This overactivity is characteristic of mild cognitive impairment (MCI) due
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *